Physician profile
Srinivasa Murthy
NPI 1922034388
$3,574.90
in general payments reported to CMS, 2019-2025
19 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $267 · 2021: $353 · 2022: $938 · 2023: $421 · 2024: $611 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,410.27 | 2019-2024 | Xarelto |
| Ironwood Pharmaceuticals, INC | $490.34 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $245.20 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $196.45 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $174.75 | 2019-2024 | |
| Stryker Corporation | $171.37 | 2025 | Mako |
| Amgen INC. | $130.89 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $120.98 | 2024 | Voquezna |
| Astellas Pharma US INC | $115.94 | 2020-2022 | |
| Glaxosmithkline, LLC. | $103.63 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $102.36 | 2019 | |
| Amarin Pharma, INC. | $89.60 | 2019 | |
| Ucb, INC. | $75.75 | 2022-2024 | Briviact |
| Novo Nordisk INC | $47.81 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $28.92 | 2020-2024 | Mounjaro, Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $23.32 | 2021 | |
| Harmony Biosciences LLC | $19.71 | 2024 | |
| Sanofi-Aventis U.S. LLC | $16.33 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivasa Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.